Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions

Acta Pharmacol Sin. 2019 Jun;40(6):833-849. doi: 10.1038/s41401-018-0173-9. Epub 2018 Oct 16.

Abstract

ShenMai, an intravenous injection prepared from steamed Panax ginseng roots (Hongshen) and Ophiopogon japonicus roots (Maidong), is used as an add-on therapy for coronary artery disease and cancer; saponins are its bioactive constituents. Since many saponins inhibit human organic anion-transporting polypeptides (OATP)1B, this investigation determined the inhibition potencies of circulating ShenMai saponins on the transporters and the joint potential of these compounds for ShenMai-drug interaction. Circulating saponins and their pharmacokinetics were characterized in rats receiving a 30-min infusion of ShenMai at 10 mL/kg. Inhibition of human OATP1B1/1B3 and rat Oatp1b2 by the individual saponins was investigated in vitro; the compounds' joint inhibition was also assessed in vitro and the data was processed using the Chou-Talalay method. Plasma protein binding was assessed by equilibrium dialysis. Altogether, 49 saponins in ShenMai were characterized and graded into: 10-100 μmol/day (compound doses from ShenMai; 7 compounds), 1-10 μmol/day (17 compounds), and <1 μmol/day (25 compounds, including Maidong ophiopogonins). After dosing, circulating saponins were protopanaxadiol-type ginsenosides Rb1, Rb2, Rc, Rd, Ra1, Rg3, Ra2, and Ra3, protopanaxatriol-type ginsenosides Rg1, Re, Rg2, and Rf, and ginsenoside Ro. The protopanaxadiol-type ginsenosides exhibited maximum plasma concentrations of 2.1-46.6 μmol/L, plasma unbound fractions of 0.4-1.0% and terminal half-lives of 15.6-28.5 h (ginsenoside Rg3, 1.9 h), while the other ginsenosides exhibited 0.1-7.7 μmol/L, 20.8-99.2%, and 0.2-0.5 h, respectively. The protopanaxadiol-type ginsenosides, ginsenosides without any sugar attachment at C-20 (except ginsenoside Rf), and ginsenoside Ro inhibited OATP1B3 more potently (IC50, 0.2-3.5 µmol/L) than the other ginsenosides (≥22.6 µmol/L). Inhibition of OATP1B1 by ginsenosides was less potent than OATP1B3 inhibition. Ginsenosides Rb1, Rb2, Rc, Rd, Ro, Ra1, Re, and Rg2 likely contribute the major part of OATP1B3-mediated ShenMai-drug interaction potential, in an additive and time-related manner.

Keywords: ShenMai injection; drug interactions; ginsenoside; herbal medicine; organic anion-transporting polypeptide 1B.

MeSH terms

  • Administration, Intravenous
  • Animals
  • Drug Combinations
  • Drug Interactions
  • Drugs, Chinese Herbal / administration & dosage
  • Drugs, Chinese Herbal / chemistry
  • Drugs, Chinese Herbal / metabolism
  • Drugs, Chinese Herbal / pharmacokinetics*
  • Ginsenosides / administration & dosage
  • Ginsenosides / blood
  • Ginsenosides / metabolism
  • Ginsenosides / pharmacokinetics*
  • Humans
  • Liver-Specific Organic Anion Transporter 1 / antagonists & inhibitors*
  • Liver-Specific Organic Anion Transporter 1 / metabolism
  • Male
  • Ophiopogon / chemistry
  • Panax / chemistry
  • Protein Binding
  • Rats, Sprague-Dawley
  • Solute Carrier Organic Anion Transporter Family Member 1B3 / antagonists & inhibitors*
  • Solute Carrier Organic Anion Transporter Family Member 1B3 / metabolism

Substances

  • Drug Combinations
  • Drugs, Chinese Herbal
  • Ginsenosides
  • Liver-Specific Organic Anion Transporter 1
  • SLCO1B1 protein, human
  • SLCO1B3 protein, human
  • Slco1b2 protein, rat
  • Solute Carrier Organic Anion Transporter Family Member 1B3
  • fructus schizandrae, radix ginseng, radix ophiopogonis drug combination